查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2157207

鉤端螺旋體病疫苗市場：全球市場預測，2026-2032年

Leptospirosis Vaccine Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，鉤端螺旋體病疫苗市場規模將達到 1,085,420,000 美元，年複合成長率為 5.91%。

主要市場統計數據
基準年 2025 7.2588億美元
預計年份：2026年 7.7295億美元
預測年份 2032 1,085,420,000 美元
複合年成長率 (%) 5.91%

鉤端螺旋體病疫苗：概述

鉤端螺旋體病是由鉤端螺旋體引起的通用感染疾病，可透過接觸洪水、暴雨、農業活動後受污染的水或土壤，或接觸受感染的動物而傳播。疫苗接種的使用取決於各國的疾病負擔、職業暴露、公共衛生政策、產品核准情況以及監測和診斷系統的可用性。人類疫苗接種政策因國家而異，但獸醫免疫是更廣泛的疾病控制計劃的關鍵組成部分。

氣候、都市化和「同一健康」如何改變預防措施。

頻繁的洪水和降雨模式的變化會增加人類暴露於受污染環境的風險，尤其是在排水、衛生和住宅基礎設施不足的地區。快速的都市化也會加劇非正式居住和老鼠罹患嚴重的地區的暴露風險。這些壓力促使公共衛生、獸醫、環境和緊急管理部門加強合作。因此，預防工作正朝著「同一健康」理念的方向發展，更加重視風險評估、職業防護、動物疫苗接種、環境控制和病例快速識別，並根據需要進行人類疫苗接種。

利用人工智慧技術監測和識別反制目標

人工智慧（AI）可透過整合氣候、水文、土地利用、動物健康、檢查室和臨床數據來識別高風險區域，進而協助鉤端螺旋體病防治。機器學習工具可以幫助確定現場調查的優先順序、改善診斷決策、檢測異常疫情，並最佳化疫苗和防護資源的分配。其價值取決於資料的代表性、檢查室驗證、透明的檢驗、隱私保護以及持續的專家監督。人工智慧是對公共衛生監測、臨床決策和社區參與的補充，而非替代。

地區差異將決定疫苗接種策略。

在北美，職業和休閒暴露預防、檢查室和有針對性的風險溝通是重點，疫苗接種政策則根據國家批准和證據制定。在拉丁美洲，由於洪水、農業、衛生和動物接觸等暴露途徑差異很大，綜合疫情應對尤為重要。歐洲的特點是檢查室和監管能力強大，且暴露模式多樣，包括旅行、休閒、農業和氣候相關事件。在中東，必須關注特定區域的水和動物暴露、移民和職業工作者以及跨境監測。非洲的優先事項包括改善診斷途徑、在農村地區提供醫療保健、發現疫情、協調獸醫和公共衛生工作。亞太地區風險環境多樣，從高密度城市環境到熱帶農業區和島嶼社區，需要採取在地化的監測、預防和免疫策略。

區域合作加強「同一健康」合作

東協成員國可從在防洪準備、實驗室診斷、跨境檢查室以及氣候相關環境下的職業防護等方面的共用中獲益。金磚國家涵蓋了流行病學和醫療衛生系統的多種情況，這為在診斷、疫苗研發、獸醫措施和疫情應對方面開展合作創造了機會。歐盟可以支持監測、證據評估和技術指導的協調統一，同時確保各國對免疫政策的責任得以共用。七國集團合作可以加強調查協調、氣候與衛生防備以及對韌性檢測網路的支持。海灣合作理事會成員國可以專注於針對職業暴露、輸入性感染疾病、水資源管理和流動人口的協調衛生防護。北約成員國可以從軍事相關人員、人道行動、災害應變和現場醫療監測的互通性指導中獲益。

每個國家的優先事項都因疫情情勢和政策環境而異。

澳洲的優先事項包括在農村地區、熱帶地區、易澇地區以及與動物接觸的環境中進行監測和預防工作。巴西的鉤端螺旋體病、洪水、城市衛生和農業暴露之間存在著密切的相互關係，因此需要採取公共衛生和環境措施的綜合方法。加拿大的因應策略取決於職業、休閒、野生動物和區域環境風險。中國需要在人口稠密的都市區、農業區、動物健康和防洪響應方面進行協調。法國、德國、義大利、西班牙和英國可以在現有衛生系統的基礎上，應對職業、旅行、休閒和氣候相關的暴露風險。印度的需求包括都市區監測、季風相關防災準備、取得檢測實驗室服務以及保護農業工人和環衛工人。日本和韓國需要根據具體情況關注職業、環境、旅行和動物相關的暴露風險。墨西哥的優先事項包括防洪準備、都市區衛生以及及時獲得診斷服務。俄羅斯的因應措施必須考慮到區域氣候變遷、農業和野生動物的影響範圍，以及各檢測機構之間的協調。美國則強調基於風險的預防、職業指南、監測以及應對洪水和動物接觸的準備。

優先考慮基於風險的預防和證據生成。

產業和公共衛生領導者必須先確定有明確暴露風險的人口和環境，然後使疫苗政策與國家監管要求和當地相關證據保持一致。投資應支持可靠的檢查室確診、人畜綜合監測、已批准疫苗接種區域的冷鏈和配送系統，以及向工人和社區清晰地傳播訊息。與環境和獸醫部門合作可以提高疫情預測的準確性。使用後監測應評估安全性、疫苗接種率、有效性和操作可行性。人工智慧試點計畫應基於明確的應用情境、檢驗的數據和可衡量的公共衛生結果啟動。

負責任的執行摘要撰寫和調查方法

本概要以所提供的市場主題為參考，並應用實證公共衛生架構。它整合了關於鉤端螺旋體病傳播途徑、環境和職業風險、「同一健康」理念下的預防、監測、疫苗接種政策以及新型分析工具的既有知識。區域、群體和國家說明均採用定性方法，避免未經證實的數字論點。本概要不包含市場估計、預測、市場佔有率或公司特定評估。有關國家和地區分類的觀察在實際應用前，應根據最新的國家指南、監管決定、流行病學報告和同行評審的證據進行檢驗。

綜合預防是永續措施的核心。

鉤端螺旋體病疫苗策略不能脫離衛生、防洪、動物健康措施、工人保護、診斷和及時治療等因素而孤立地看待。由於地域差異，單一的全球政策不太可能適用。以風險為基礎的決策應反映當地的感染模式、醫療衛生系統能力和現有證據。透過「同一健康」理念加強合作、負責任地使用人工智慧以及對監測和分發系統進行有針對性的投資，有助於在加強防範的同時，支持更安全、更公平的預防工作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 鉤端螺旋體病疫苗市場：依動物種類分類

  • 狗
  • 牛
  • 馬
  • 豬

第8章：鉤端螺旋體病疫苗市場：依疫苗類型分類

  • 失活
    • 部分失活
    • 全細胞
  • 減毒活病毒疫苗
  • 重組
    • DNA
    • 次單元

第9章：鉤端螺旋體疫苗市場：依通路分類

  • 醫院藥房
  • 網路商店
  • 零售藥房
  • 動物診所

第10章：鉤端螺旋體病疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 口服
  • 皮下

第11章：鉤端螺旋體疫苗市場：以劑型分類

  • 液體
  • 冷凍乾燥製劑

第12章：鉤端螺旋體疫苗市場：依最終用戶分類

  • 商業農場
  • 診斷檢查室
  • 研究機構
  • 動物醫院

第13章：鉤端螺旋體疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：鉤端螺旋體疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：鉤端螺旋體病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Colorado Serum Company
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • Hipra SA
  • Indian Immunologicals Ltd.
  • Institutul Pasteur
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Venkateshwara Hatcheries Pvt. Ltd.
  • Vetoquinol SA
  • Zoetis Inc.

第18章 主要專家

Product Code: MRR-EF0BD2D829FE

The Leptospirosis Vaccine Market is projected to grow by USD 1,085.42 million at a CAGR of 5.91% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 725.88 million
Estimated Year [2026] USD 772.95 million
Forecast Year [2032] USD 1,085.42 million
CAGR (%) 5.91%

Leptospirosis Vaccines: Executive Overview

Leptospirosis is a zoonotic bacterial disease caused by Leptospira species and transmitted through exposure to contaminated water or soil, often following flooding, heavy rainfall, agricultural activity, or contact with infected animals. Vaccine use is shaped by national disease burden, occupational exposure, public-health policy, product authorization, and the availability of surveillance and diagnostic systems. Human vaccination policies differ considerably by country, while veterinary immunization is an important component of broader disease-control programs.

How Climate, Urbanization, and One Health Are Reshaping Prevention

More frequent flooding and changing rainfall patterns can increase opportunities for human contact with contaminated environments, particularly where drainage, sanitation, and housing infrastructure are limited. Rapid urbanization may also intensify exposure in informal settlements and areas with rodent infestation. These pressures are encouraging closer coordination among public-health, veterinary, environmental, and emergency-management authorities. The resulting shift toward One Health prevention places greater emphasis on risk mapping, occupational protection, animal vaccination, environmental control, and rapid case recognition alongside human vaccination where appropriate.

Artificial Intelligence Strengthens Surveillance and Targeting

Artificial intelligence can support leptospirosis control by combining climate, hydrology, land-use, animal-health, laboratory, and clinical data to identify areas of heightened risk. Machine-learning tools may help prioritize field investigations, improve diagnostic decision support, detect unusual clusters, and optimize allocation of vaccines and protective resources. Their value depends on representative data, laboratory confirmation, transparent validation, privacy safeguards, and continued expert oversight. AI should complement-not replace-public-health surveillance, clinical judgment, and community engagement.

Regional Differences Define Vaccine Strategy

North America generally emphasizes occupational and recreational exposure prevention, laboratory surveillance, and targeted risk communication, with vaccination policies determined by national authorization and evidence. Latin America faces substantial variation in exposure related to flooding, agriculture, sanitation, and animal contact, making integrated outbreak preparedness especially important. Europe combines strong laboratory and regulatory capacity with heterogeneous exposure patterns, including travel, recreation, farming, and climate-related events. The Middle East requires attention to localized water and animal exposures, migrant and occupational populations, and cross-border surveillance. Africa's priorities include improving diagnostic access, rural health delivery, outbreak detection, and veterinary-public-health coordination. Asia-Pacific contains diverse risk environments-from dense urban settings to tropical agricultural and island communities-requiring locally tailored surveillance, prevention, and immunization approaches.

Regional Blocs Reinforce Coordinated One Health Action

ASEAN members benefit from sharing approaches to flood preparedness, laboratory confirmation, cross-border surveillance, and occupational protection across climatically connected settings. BRICS countries encompass diverse epidemiological and health-system contexts, creating opportunities for collaboration in diagnostics, vaccine research, veterinary control, and outbreak response. The European Union can support harmonized surveillance, evidence assessment, and movement of technical guidance while retaining national responsibility for immunization policy. G7 cooperation can strengthen research coordination, climate-health preparedness, and support for resilient laboratory networks. GCC countries can focus on occupational exposure, imported infections, water management, and coordinated health protection for mobile populations. NATO members may benefit from interoperable guidance for military personnel, humanitarian operations, disaster response, and field medical surveillance.

Country Priorities Vary by Exposure and Policy Context

Australia's priorities include surveillance and prevention for rural, tropical, flood-affected, and animal-contact settings. Brazil faces important links between leptospirosis, flooding, urban sanitation, and agricultural exposure, supporting integrated public-health and environmental action. Canada's approach is shaped by occupational, recreational, wildlife, and regional environmental risks. China requires coordination across dense urban areas, agricultural zones, animal health, and flood response. France, Germany, Italy, Spain, and the United Kingdom can build on established health systems while addressing occupational, travel-related, recreational, and climate-associated exposures. India's needs include rural and urban surveillance, monsoon-related preparedness, laboratory access, and protection for agricultural and sanitation workers. Japan and South Korea require context-specific attention to occupational, environmental, travel, and animal-associated exposure. Mexico's priorities include flood preparedness, rural and urban sanitation, and access to timely diagnosis. Russia's response must account for regional climatic variation, agricultural and wildlife exposure, and laboratory connectivity. The United States emphasizes risk-based prevention, occupational guidance, surveillance, and preparedness for flooding and animal contact.

Prioritize Risk-Based Prevention and Evidence Generation

Industry and public-health leaders should first define populations and settings with demonstrable exposure risk, then align vaccine policy with national regulatory requirements and locally relevant evidence. Investment should support reliable laboratory confirmation, integrated human and animal surveillance, cold-chain and delivery capabilities where vaccination is authorized, and clear communication for workers and communities. Partnerships with environmental and veterinary authorities can improve outbreak anticipation, while post-use monitoring should assess safety, uptake, effectiveness, and operational feasibility. AI pilots should begin with well-defined use cases, validated data, and measurable public-health outcomes.

Methodology for a Responsible Executive Summary

This summary uses the supplied market topic as a subject reference and applies an evidence-led public-health framework. It synthesizes established knowledge about leptospirosis transmission, environmental and occupational risk, One Health prevention, surveillance, vaccination policy, and emerging analytical tools. Regional, group, and country narratives are presented qualitatively and avoid unsupported numerical claims. No market estimates, forecasts, market shares, or company-specific assessments are included. Country and bloc observations should be validated against current national guidelines, regulatory decisions, epidemiological reports, and peer-reviewed evidence before operational use.

Integrated Prevention Is Central to Sustainable Control

Leptospirosis vaccine strategy cannot be separated from sanitation, flood resilience, animal-health measures, occupational protection, diagnostics, and timely treatment. Geographic differences mean that a single global policy is unlikely to be appropriate; risk-based decisions should reflect local transmission patterns, health-system capacity, and available evidence. Stronger One Health coordination, responsible use of AI, and targeted investment in surveillance and delivery systems can improve preparedness while supporting safer and more equitable prevention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Leptospirosis Vaccine Market, by Animal Species

  • 7.1. Introduction
  • 7.2. Canine
  • 7.3. Cattle
  • 7.4. Equine
  • 7.5. Swine

8. Leptospirosis Vaccine Market, by Vaccine Type

  • 8.1. Introduction
  • 8.2. Inactivated
    • 8.2.1. Fractional
    • 8.2.2. Whole Cell
  • 8.3. Live Attenuated
  • 8.4. Recombinant
    • 8.4.1. DNA
    • 8.4.2. Subunit

9. Leptospirosis Vaccine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Stores
  • 9.4. Retail Pharmacies
  • 9.5. Veterinary Clinics

10. Leptospirosis Vaccine Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Leptospirosis Vaccine Market, by Dose Form

  • 11.1. Introduction
  • 11.2. Liquid
  • 11.3. Lyophilized

12. Leptospirosis Vaccine Market, by End User

  • 12.1. Introduction
  • 12.2. Commercial Farms
  • 12.3. Diagnostic Laboratories
  • 12.4. Research Institutes
  • 12.5. Veterinary Hospitals

13. Leptospirosis Vaccine Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Leptospirosis Vaccine Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Leptospirosis Vaccine Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Biogenesis Bago S.A.
  • 17.2. Boehringer Ingelheim International GmbH
  • 17.3. Ceva Sante Animale S.A.
  • 17.4. Colorado Serum Company
  • 17.5. Elanco Animal Health Incorporated
  • 17.6. Hester Biosciences Limited
  • 17.7. Hipra S.A.
  • 17.8. Indian Immunologicals Ltd.
  • 17.9. Institutul Pasteur
  • 17.10. Merck & Co. Inc.
  • 17.11. Pfizer Inc.
  • 17.12. Sanofi Pasteur S.A.
  • 17.13. Venkateshwara Hatcheries Pvt. Ltd.
  • 17.14. Vetoquinol S.A.
  • 17.15. Zoetis Inc.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Leptospirosis Vaccine Market, Years Considered for the Study
  • FIGURE 2. Global Leptospirosis Vaccine Market, Research Design
  • FIGURE 3. Global Leptospirosis Vaccine Market, Research Framework
  • FIGURE 4. Global Leptospirosis Vaccine Market, Data Triangulation
  • FIGURE 5. Global Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Leptospirosis Vaccine Market Size, by Animal Species, 2025 vs 2032 (%)
  • FIGURE 7. Global Leptospirosis Vaccine Market Size, by Animal Species, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Leptospirosis Vaccine Market Size, by Vaccine Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Leptospirosis Vaccine Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Leptospirosis Vaccine Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 11. Global Leptospirosis Vaccine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Leptospirosis Vaccine Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Leptospirosis Vaccine Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Leptospirosis Vaccine Market Size, by Dose Form, 2025 vs 2032 (%)
  • FIGURE 15. Global Leptospirosis Vaccine Market Size, by Dose Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Leptospirosis Vaccine Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Leptospirosis Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Leptospirosis Vaccine Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Leptospirosis Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Leptospirosis Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Leptospirosis Vaccine Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Leptospirosis Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Leptospirosis Vaccine Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Leptospirosis Vaccine Market Segmentation & Coverage
  • TABLE 2. Global Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 4. Global Canine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Canine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Canine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Cattle Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Cattle Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Cattle Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Equine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Equine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Equine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Swine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Swine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Swine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 17. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Fractional Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Fractional Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Fractional Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Whole Cell Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Whole Cell Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Whole Cell Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global DNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global DNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global DNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 39. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Online Stores Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Online Stores Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Online Stores Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Veterinary Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Veterinary Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Veterinary Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 52. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 62. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Lyophilized Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Lyophilized Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Lyophilized Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 69. Global Commercial Farms Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Commercial Farms Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Commercial Farms Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Veterinary Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Veterinary Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Veterinary Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Asia-Pacific Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Asia-Pacific Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 91. North America Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. North America Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 93. North America Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 94. North America Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 95. North America Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 96. North America Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. North America Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 98. North America Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 99. North America Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 100. Latin America Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Latin America Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 102. Latin America Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 103. Latin America Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 104. Latin America Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 105. Latin America Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 106. Latin America Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 107. Latin America Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 108. Latin America Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. Europe Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Europe Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 111. Europe Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 112. Europe Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 113. Europe Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 114. Europe Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. Europe Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 116. Europe Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 117. Europe Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. Middle East Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Middle East Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 120. Middle East Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 121. Middle East Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 122. Middle East Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 123. Middle East Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 124. Middle East Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 125. Middle East Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 126. Middle East Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 127. Africa Leptospirosis Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Africa Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 129. Africa Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 130. Africa Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 131. Africa Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 132. Africa Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 133. Africa Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 134. Africa Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 135. Africa Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. Global Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. ASEAN Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 138. ASEAN Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 139. ASEAN Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 140. ASEAN Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 141. ASEAN Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 142. ASEAN Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. ASEAN Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 144. ASEAN Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 145. ASEAN Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. GCC Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. GCC Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 148. GCC Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 149. GCC Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 150. GCC Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 151. GCC Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. GCC Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. GCC Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 154. GCC Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 155. European Union Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 156. European Union Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 157. European Union Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 158. European Union Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 159. European Union Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 160. European Union Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. European Union Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 162. European Union Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 163. European Union Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. BRICS Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. BRICS Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 166. BRICS Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 167. BRICS Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 168. BRICS Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 169. BRICS Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. BRICS Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 171. BRICS Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 172. BRICS Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 173. G7 Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. G7 Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 175. G7 Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 176. G7 Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 177. G7 Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 178. G7 Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. G7 Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 180. G7 Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 181. G7 Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. NATO Leptospirosis Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 183. NATO Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 184. NATO Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 185. NATO Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 186. NATO Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 187. NATO Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 188. NATO Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 189. NATO Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 190. NATO Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 191. Global Leptospirosis Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 192. United States Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 193. United States Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 194. United States Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 195. United States Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 196. United States Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 197. United States Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. United States Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 199. United States Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 200. United States Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 201. Canada Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 202. Canada Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 203. Canada Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 204. Canada Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 205. Canada Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 206. Canada Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Canada Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 208. Canada Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 209. Canada Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 210. Mexico Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 211. Mexico Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 212. Mexico Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 213. Mexico Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 214. Mexico Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 215. Mexico Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 216. Mexico Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 217. Mexico Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 218. Mexico Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 219. Brazil Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 220. Brazil Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 221. Brazil Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 222. Brazil Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 223. Brazil Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 224. Brazil Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 225. Brazil Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. Brazil Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 227. Brazil Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 228. United Kingdom Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 229. United Kingdom Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 230. United Kingdom Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 231. United Kingdom Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 232. United Kingdom Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 233. United Kingdom Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. United Kingdom Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 235. United Kingdom Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 236. United Kingdom Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 237. Germany Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 238. Germany Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 239. Germany Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 240. Germany Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 241. Germany Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 242. Germany Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 243. Germany Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. Germany Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 245. Germany Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 246. France Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 247. France Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 248. France Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 249. France Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 250. France Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 251. France Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 252. France Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 253. France Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 254. France Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 255. Russia Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 256. Russia Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 257. Russia Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 258. Russia Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 259. Russia Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 260. Russia Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. Russia Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 262. Russia Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 263. Russia Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 264. Italy Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 265. Italy Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 266. Italy Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 267. Italy Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 268. Italy Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 269. Italy Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 270. Italy Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 271. Italy Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 272. Italy Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 273. Spain Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 274. Spain Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 275. Spain Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 276. Spain Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 277. Spain Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 278. Spain Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. Spain Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 280. Spain Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 281. Spain Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 282. China Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 283. China Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 284. China Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 285. China Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 286. China Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 287. China Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 288. China Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 289. China Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 290. China Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 291. India Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 292. India Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 293. India Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 294. India Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 295. India Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 296. India Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 297. India Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 298. India Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 299. India Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 300. Japan Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 301. Japan Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 302. Japan Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 303. Japan Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 304. Japan Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 305. Japan Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 306. Japan Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 307. Japan Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 308. Japan Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 309. Australia Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 310. Australia Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 311. Australia Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 312. Australia Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 313. Australia Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 314. Australia Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 315. Australia Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. Australia Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 317. Australia Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 318. South Korea Leptospirosis Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 319. South Korea Leptospirosis Vaccine Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 320. South Korea Leptospirosis Vaccine Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 321. South Korea Leptospirosis Vaccine Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 322. South Korea Leptospirosis Vaccine Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 323. South Korea Leptospirosis Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 324. South Korea Leptospirosis Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 325. South Korea Leptospirosis Vaccine Market Size, by Dose Form, 2017-2032 (USD Million)
  • TABLE 326. South Korea Leptospirosis Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 327. Global Leptospirosis Vaccine Market Share, by Key Player, 2025
  • TABLE 328. Global Leptospirosis Vaccine Market, Key Experts